The Cardioprotective Effect of Mildronate is Diminished After Co-Treatment With l-Carnitine
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Mildronate, an inhibitor of l-carnitine biosynthesis and uptake, is a cardioprotective drug whose mechanism of action is thought to rely on the changes in concentration of l-carnitine in heart tissue. In the present study, we compared the cardioprotective effect of mildronate (100 mg/kg) and a combination of mildronate and l-carnitine (100 + 100 mg/kg) administered for 14 days with respect to the observed changes in l-carnitine level and carnitine palmitoyltransferase I (CPT-I)-dependent fatty acid metabolism in the heart tissues. Concentrations of l-carnitine and its precursor γ-butyrobetaine (GBB) were measured by ultraperformance liquid chromatography with tandem mass spectrometry. In addition, mitochondrial respiration, activity of CPT-I, and expression of CPT-IA/B messenger RNA (mRNA) were measured. Isolated rat hearts were subjected to ischemia–reperfusion injury. Administration of mildronate induced a 69% decrease in l-carnitine concentration and a 6-fold increase in GBB concentration in the heart tissue as well as a 27% decrease in CPT-I-dependent mitochondrial respiration on palmitoyl-coenzyme A. In addition, mildronate treatment induced a significant reduction in infarct size and also diminished the ischemia-induced respiration stimulation by exogenous cytochrome c. Treatment with a combination had no significant impact on l-carnitine concentration, CPT-I-dependent mitochondrial respiration, and infarct size. Our results demonstrated that the mildronate-induced decrease in l-carnitine concentration, concomitant decrease in fatty acid transport, and maintenance of the intactness of outer mitochondrial membrane in heart mitochondria are the key mechanisms of action for the anti-infarction activity of mildronate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Disorders of carnitine transport and the carnitine cycle
Longo, N., Amat di San Filippo, C., & Pasquali, M. (2006) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30087 · Cited by 543
Stephens, F. B., Constantin‐Teodosiu, D., & Greenhaff, P. L. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2006.125799 · Cited by 396 · cited 2×
“L-Carnitine is a cofactor required for the transport of long-chain fatty acids (FAs) into the mitochondria and for the regulation of cellular energy metabolism.(1,2) Mildronate (3-[2,2,2-trimethylhydrazinium] propionate) is a pharmacological agent that decreases the level of L-carnitine in plasma and in heart tissue(3…”
BackgroundCarnitine, mitochondrial function and therapy
Zammit, V. A., Ramsay, R. R., Bonomini, M., & Arduini, A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.024 · Cited by 149 · cited 3×
“L-Carnitine is a cofactor required for the transport of long-chain fatty acids (FAs) into the mitochondria and for the regulation of cellular energy metabolism.(1,2) Mildronate (3-[2,2,2-trimethylhydrazinium] propionate) is a pharmacological agent that decreases the level of L-carnitine in plasma and in heart tissue(3…”
BackgroundL-Carnitine dissimilation in the gastrointestinal tract of the rat
Rebouche, C. J., Mack, D. L., & Edmonson, P. F. (1984) · Biochemistry · doi:10.1021/bi00321a022 · Cited by 67
Cited by
Kuka, J., Liepinsh, E., Makrecka-Kuka, M., Liepins, J., Cirule, H., Gustina, D., Loza, E., Zharkova-Malkova, O., Grinberga, S., Pugovics, O., et al. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.09.028 · Cited by 97
Self-citationStory behind meldonium–from pharmacology to performance enhancement: a narrative review
Schobersberger, W., Dünnwald, T., Gmeiner, G., & Blank, C. (2017) · British Journal of Sports Medicine · doi:10.1136/bjsports-2016-096357 · Cited by 61
Dambrova, M., Skapare‐Makarova, E., Konrade, I., Pugovics, O., Grinberga, S., Tirzite, D., Petrovska, R., Kalvins, I., & Liepins, E. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.135 · Cited by 63
“Meldonium (mildronate; 3‐(2,2,2‐trimethylhydrazinium) propionate dehydrate) is an anti‐ischemic and anti‐atherosclerotic drug that exerts its cardioprotective action through an L‐carnitine‐lowering effect.(1,2) The long‐term administration of mildronate also significantly lowers the L‐carnitine plasma concentrations i…”
BackgroundSelf-citation
Metadata
- Authors
- Kuka, J., Vilskersts, R., Cirule, H., Makrecka, M., Pugovics, O., Kalvinsh, I., Dambrova, M., & Liepinsh, E.
- Venue
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2011-09-08
- Volume
- 17
- Issue
- 2
- Pages
- 215-222
- ISSN
- 1074-2484 (ISSN-L)
- 1940-4034
- OpenAlex
- W2156618906
- Cited by
- 53
- References
- 4
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Cardioprotective Effect of Mildronate is Diminished After Co-Treatment With l-Carnitine. https://app.cochat.ai/papers/10.1177/1074248411419502
- The paper
- Kuka, J., Vilskersts, R., Cirule, H., Makrecka, M., Pugovics, O., Kalvinsh, I., Dambrova, M., & Liepinsh, E. (2012). The Cardioprotective Effect of Mildronate is Diminished After Co-Treatment With l-Carnitine. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/1074248411419502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.